

#5  
YC  
4/15/03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Examiner : William R A Jarvis  
Applicant(s) : BHF Wong, et al.  
Serial Number : 10/035,100  
Filed : December 28, 2001  
For : New Drug Combination

RECEIVED  
APR 11 2003  
TECH CENTER 1600/2900

Commissioner of Patents and Trademarks  
Washington, DC 20231

## ELECTION OF SPECIES PURSUANT TO 37 CFR 1.143

Sir:

This is a response to the Office Communication mailed March 26, 2003.

## STATUS OF CLAIMS

Claims 1-22 are pending in the application, and are subject to a restriction or election requirement.

The Office finds that the claims are generic to a plurality of disclosed patentably distinct species comprising (a) one or more norepinephrine inhibitors and (b) one or more neuroleptic agents.


## ELECTION

Applicants elect reboxetine from group (a) and clozapine from group (b). Structures are provided on the attached Exhibit as requested by the Office.

## INVENTORSHIP

No change in inventorship is necessitated by reason of this election.

Respectfully submitted,



Stephen L. Nesbitt, Attorney  
Registration No. 28,981

Date: April 4, 2003

Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, Michigan 49001


Telephone No. (616) 833-1837 or (616) 833-9500  
Telefax o. (616) 833-8897 or (616) 833-2316




Exhibit

PATENT/Docket No. 00378.US1  
Serial No. 10/035,100  
Page 3

RECEIVED  
APR 11 2003  
TECH CENTER 1600/2900



Reboxetine



Clozapine